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Background: Computational systems models may allow understanding of progression and impairment of apoptosis based
on quantitative protein profiles.
Results: We found apoptosis to be impaired in some cell lines after MOMP, which can be understood by our systems model
“APOPTO-CELL”.
Conclusion: APOPTO-CELL helps to understand heterogeneity in apoptosis execution after MOMP.
Significance: APOPTO-CELL may help to assess cancer-specific efficacy of chemotherapeutics that induce apoptosis.
Deregulation of apoptosis is a hallmark of carcinogenesis.
We here combine live cell imaging and systems modeling
to investigate caspase-dependent apoptosis execution subse-
quent to mitochondrial outer membrane permeabilization
(MOMP) in several cancer cell lines. We demonstrate that,
although most cell lines that underwent MOMP also showed
robust and fast activation of executioner caspases and apo-
ptosis, the colorectal cancer cell lines LoVo and HCT-116
Smac/, similar to X-linked inhibitor of apoptosis protein
(XIAP)-overexpressing HeLa (HeLa XIAPAdv) cells, only
showed delayed and often no caspase activation, suggesting
apoptosis impairment subsequent to MOMP. Employing
APOPTO-CELL, a recently established model of apoptosis
subsequent to MOMP, this impairment could be understood
by studying the systemic interaction of five proteins that are
present in the apoptosis pathway subsequent to MOMP.
Using APOPTO-CELL as a tool to study detailed molecular
mechanisms during apoptosis execution in individual cell
lines, we demonstrate that caspase-9 was the most important
regulator in DLD-1, HCT-116, and HeLa cells and identified
additional cell line-specific co-regulators. Developing and
applying a computational workflow for parameter screening,
systems modeling identified that apoptosis execution kinet-
ics are more robust against changes in reaction kinetics in
HCT-116 and HeLa than in DLD-1 cells. Our systems model-
ing study is the first to draw attention to the variability in cell
specific protein levels and reaction rates and to the emergent
effects of such variability on the efficiency of apoptosis
execution and on apoptosis impairment subsequent to
MOMP.
Resistance of cancer cells to chemotherapy is in part associ-
atedwith impairment of programmed cell death. Therefore, the
understanding of themolecular, and often cancer- and patient-
specific, mechanisms of such impairment may aid in designing
more effective and patient-stratified treatment regimes.
The majority of state-of-the-art chemotherapeutics induce
the mitochondrial pathway of apoptosis (1–3). This pathway is
characterized by a two-step procedure separated by the process
ofmitochondrial outermembrane permeabilization (MOMP).3
Recent research has studied the processes prior toMOMP that
are governed by the interplay of proteins of the BCL-2 protein
family and found that this interplay can lead either to MOMP
execution or to its impairment (4). Further studies then related
MOMP impairment to the likelihood of chemo-resistance and
to the success of cancer treatment (5). In contrast, the questions
of whether or not and how apoptosis can be impaired subse-
quent to MOMP in cancer cells have not yet been sufficiently
addressed. Because evidence that key players involved in apo-
ptosis execution subsequent to MOMP have been identified as
predictive markers for cancer treatment (3), investigating the
importance in regulating apoptosis after MOMP is desirable.
Studies of apoptosis, both prior to and after MOMP, can
benefit from employing computational systemsmodels. Unlike
classical biochemical approaches, where attention is focused on
one or a few proteins, systems models help to understand how
more complex pathways are regulated, how pathways cross-
talk, and which pathway branches are more relevant than oth-
ers (6–8). Several systems models investigating apoptosis exe-
cution are currently available, including those that are purely
theoretical (9, 10), some that have been combined with bio-
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chemistry (11–13), and others that have been validated by sin-
gle cell imaging (14–18).
To study themitochondrial pathway of apoptosis subsequent
toMOMP,we previously developed the computational systems
model APOPTO-CELL (17, 19). As input, APOPTO-CELL
requires absolute levels of five proteins: the pro-apoptotic pro-
teins APAF-1, Smac, procaspase-3, and procaspase-9 and the
anti-apoptotic protein XIAP. Assuming that MOMP has
occurred, APOPTO-CELL calculates the time profile of con-
centrations for all proteins. It further quantifies apoptosis exe-
cution kinetics (speed) by calculating the amount of cellular
substrate that gets cleaved over time.
In this study, we found that apoptosis can be impaired in
some cancer cell lines subsequent to MOMP and that this
impairment can be explained using APOPTO-CELL. We fur-
ther present APOPTO-CELL as a tool to study cell-specific
molecular mechanisms during apoptosis execution that arise
fromcell line individual proteinprofiles.We finally useAPOPTO-
CELL to test the robustness of apoptosis execution against fluc-
tuations in enzyme activities and provide a workflow for model
optimization.
EXPERIMENTAL PROCEDURES
Cell Culture—The human colorectal cancer cell linesDLD-1,
HCT-116, HCT-116 Smac/, breast cancer cells MCF-7 and
MCF-7/C3, and HeLa cervical cancer cell lines were main-
tained in RPMI1640 medium. Human colorectal cancer cell
lines HT-29 and LoVo were maintained in DMEM. Medium
was supplemented with 10% FCS, 2 mM L-glutamine, 100
units/ml penicillin, and 100 mg/ml streptomycin in a humidi-
fied environment containing 5% CO2 at 37 °C.
Determination of Protein Concentrations—Protein concen-
trations of procaspase-3, procaspase-9, XIAP, Apaf-1, and
Smac inDLD-1,HCT-116,HT-29, LoVo, andMCF-7 cells were
obtained by quantitativeWestern blots.HeLa cells, where abso-
lute concentrations were previously described (17), were used
as a reference for quantification. Concentrations of pro-
caspase-3, procaspase-9, Apaf-1, and Smac in the XIAP knock-
out (XIAP0/) cell lines DLD-1 XIAP0/ and HCT-116
XIAP0/ were assumed to be the same as in their parental cell
line as determined previously (20). Procaspase-3, procaspase-9,
Apaf-1, and XIAP in Smac-deficient HCT-116 Smac/ cells
were assumed to be the same as in HCT-116WT cells. Further,
caspase-3 levels in MCF-7 cells that were retransfected with
caspase-3 were determined by blotting against HeLa cells (21,
22). XIAP levels in HeLa XIAPAdv cells were obtained from
experiments performed and described previously (17).
Western blotting was performed as described (17). Briefly,
equal amounts of protein (20 g) were loaded onto SDS-poly-
acrylamide gels (10–15%). Proteins were separated at 130 V for
1.5 h and blotted to nitrocellulose membranes (Protean BA 83;
Schleicher & Schuell) in transfer buffer (25 mM Tris, 192 mM
glycine, 20%methanol (v/v), and 0.01% SDS) at 18 V for 60min.
Blots were blocked with 5% nonfat dry milk in TBST (15 mM
Tris-HCl, pH 7.5, 200 mM NaCl, and 0.1% Tween 20) at room
temperature for 2 h. Membranes were incubated with the fol-
lowing antibodies for 2 h at room temperature or overnight at
4 °C. Rabbit polyclonal antibodies specific for Apaf-1 (1:5000;
Chemicon), caspase-3 (1:2000; Cell Signaling), caspase-9
(1:2000; Pharmingen), and Smac/Diablo (1:4000; R&D Sys-
tems) were used. A mouse monoclonal XIAP antibody (1:2000;
BD Transduction Laboratories) or a rabbit polyclonal antibody
was used. Mouse monoclonal antibodies against -actin
(1:5000; Sigma) and tubulin (1:10,000; Sigma) were used in
loading controls. Membranes were washed with TBST three
times for 10 min and incubated with anti-mouse or anti-rabbit
peroxidase-conjugated secondary antibodies (1:4000; Jackson
ImmunoResearch) for 1h.Blotswerewashedanddevelopedusing
an ECL detection reagent (Amersham Biosciences). Chemilumi-
nescence signals were detected using a Fuji LAS-4000 image
acquisition system equipped with a cooled 12-bit digital CCD
camera. Digital densitometry was carried out after background
subtraction by quantifying signal intensities of the chemilumines-
cence signals. For all proteins, at least three detections were eval-
uated. S.E. and S.D. values were calculated.
Transfection and Single Cell Microscopy—Caspase-3-depen-
dent FRET disruption in DLD-1 WT, DLD-1 XIAP0/, HCT-
116WT, HCT-116 XIAP0/, MCF-7/C3, and HeLa single cells
was obtained from previous publications (17, 20, 23). De novo
measurements of apoptosis kinetics for LoVo, HT-29, and
HCT-116 Smac/ were performed using the method
described previously (17). Briefly, cells were equilibrated with
30 nM TMRM in Hepes-buffered medium (15 mM, pH 7.4),
covered withmineral oil, and placed in a heated (37 °C) incuba-
tion chamber that was mounted on the microscope stage. The
membrane-permeable, cationic probe TMRM was used to
measure the mitochondrial membrane potential. The onset of
TMRM loss that indicates depolarization of the mitochondrial
membrane potential was used as a marker for cytochrome c
release and MOMP.
Apoptosis was induced with 3 M staurosporine (STS). To
report caspase-3 activation, cells were transfected with plasmid
DNA (pmyc-CFP-DEVD-YFP (24)). Cleavage kinetics of this
substrate were detected at the single-cell level. CFP/FRET
emission ratio traces were obtained by dividing the average
fluorescence intensity values of single cells after background
subtraction. A Zeiss LSM 710 META inverted microscope
(Carl Zeiss) attached to a confocal laser-scanning unit equipped
with a 405-nm diode laser, 488-nm argon laser, and 543-nm
helium/neon laser was used. CFP, YFP, and TMRM fluores-
cence and FRET were monitored with a 63, numerical aper-
ture 1.4 oil immersion objective with the optical slice thickness
set to 1.5 m (full width at half-maximum) and detected using
optimized filter and mirror sets. Subsequently, TMRM average
intensity and CFP/FRET emission ratio traces were obtained
for fluorescent cells. Experiments were terminated 16–24 h
after STS administration. Onset of TMRM decrease and
DEVD-FRET substrate cleavage were determined visually
against the base-line signal. Image processing and analysis were
performed with MetaMorph software (Molecular Devices,
Wokingham, UK).
Experimental Apoptosis Execution Kinetics from Literature—
FRET traces for substrate cleavage for HeLa and XIAP-overex-
pressing HeLa cells were obtained from Ref. 17. Traces for
DLD-1, DLD-1 XIAP0/, HCT-116, and HCT-116 XIAP0/
cells were remodeled from data specifying onset and duration
Systems Analysis of Apoptosis Heterogeneity after MOMP
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in (20). For MCF-7/C3 cells, data were taken from Refs. 17 and
22. FRET traces were represented by a sigmoid Boltzmann
function,
FRETt 
Amax  Amin
1 et t0/dt
 Amin (Eq. 1)
Here dt is the width, Amin and Amax are minimum and maxi-
mum, and t0 is the point of inflection of the FRET signal.
Statistics—Statistical analysis was performed using
MATLAB (TheMathworks Inc., Natick, MA). Protein concen-
trations are given asmeans S.E. Single cell datawere analyzed
by analysis of variance and Student’s t test when normally dis-
tributed and given asmean S.E.Whennormality could not be
assumed, Kruskal-Wallis and Mann-Whitney test were used,
and datawere given asmedianwith interquartile range. p values
of0.05 were considered significant.
Computational Model of Mitochondrial Apoptosis—The
originalmodelwas described previously (seemain text and sup-
plemental material of Ref. 17). Briefly, MOMP was assumed to
be invoked, eventually culminating in activation of caspase-3
and cleavage of cellular substrate (model output). Quantified
protein levels of APAF-1, XIAP, procaspase-3, procaspase-9,
and Smac were used as model input. Eachmolecular interaction
wasmodeled bymass action kinetics and transformed into a set of
ordinary differential equations. Ordinary differential equations
were solved by MATLAB (The MathWorks Inc.). Mechanistic
details can be found in supplemental Table 1. The model code of
APOPTO-CELL can be obtained from the authors by request.
It was assumed that the S.E. value of quantified proteins from
three Western blot experiments partly reflects information on
cell-to-cell heterogeneity in a particular cell line (each experi-
ment is considered as a slightly biased sample) and is partly a
sign of variations in the experimental handling. As a conse-
quence, the S.E. was assumed to contain biological information
as well as experimental uncertainties, both representing valua-
ble information for the analysis of apoptosis in cell populations.
Hence, three scenarios were considered (Table 1). The first sce-
nario (“average scenario”) used the average concentrations of
three experiments as input. For the population-based analysis
of Fig. 2, an additional second and third scenario not only took
into account the average protein concentrations for each of the
above proteins and for each cell but also the S.E. over three
experiments. For the second scenario (defined as the “slow sce-
nario”), the concentration of the pro-apoptotic proteins pro-
caspase-3, procaspase-9, Smac, and Apaf-1 was set to the aver-
age concentration minus one S.E., and the concentration of the
anti-apoptotic protein XIAP was set to average concentration
plus one S.E. For the third scenario (“fast scenario”), the con-
centration of the pro-apoptotic proteins was set to the average
concentration plus one S.E., and the concentration for XIAP
was set to the average concentration minus one S.E. For the
optimizationworkflow (Figs. 5 and 6), the S.D. was used instead
of the S.E. for the slow and fast scenario, in order not to overly
restrict the criteria for parameter screening.
Methods of Parameter Assessment—Those parameters were
selected whose changes would most likely have the highest
impact on the model output. Two partially complementary
methods were employed to select the most influential parame-
ter sets and are described below. In both methods, the values of
the kinetic model parameters kj0	 were changed from the refer-
ence set k0
kj0	published inRef. 17 to a set k
kj	with changed
parameters. It was then assessed how these changes of parameter
valuesaffected thekineticsof thepredictedsubstratecleavage.The
assessment was done either for individual parameters or for
parameter combinations, depending on themethod used.
Individual Parameter Assessment (Parameter Set “I”)—In the
first assessment method (individual parameter assessment),
each parameter was multiplied separately by a series of factors
8, 4, 2, 1⁄2, 1⁄4, and 1⁄8. Subsequently, changes of the time point at
which the model predicted 80% cleavage of the cell substrate
were calculated (denoted as t80). Whenever a parameter change
resulted in less than80% substrate cleavage after 300min, the time
wascensoredat300min.Parameterswere ranked, giving thehigh-
est rank to that parameter where the time point t80 changedmost
decisively between an8-fold up- anddown-regulation.Theproce-
dure was performed for HeLa, HCT-116, and DLD-1 cells sepa-
rately assuming the “average scenario” (Fig. 4,A–C).
For studying the effects of parameter variations in all cells
and scenarios (“slow scenario,” “average scenario,” and “fast
scenario”; Table 1) simultaneously, the shifts in the predicted
t80 values between the reference APOPTO-CELL and the
model assuming parameter variations were calculated. Values
were subsequently averaged over all cells and all scenarios and
ranked according to their change between 8-fold up- and
down-regulation with the highest rank given to the parameter
with highest influence. The 10 parameterswith the highest rank
were selected as parameter set I (“individual”; Table 2).
Assessment of Parameter Cooperation (Parameter Set “C”)—
Ina secondmethod, the effect onmodel output of simultaneous
but local changes was assessed using a procedure described
TABLE 1
Parameter combination for fast, average, and slow apoptosis execution scenarios based on protein variability
Scenarios were defined to take into account variability in experimentally detected protein levels within a population (Fig. 2, A–E). A “slow” scenario assumes that the
concentration of the anti-apoptotic protein XIAP is one S.E. value higher than the average of three experiments, whereas all levels of pro-apoptotic proteins are one S.D.
value lower. An “average scenario” assumes the concentrations to be the average concentrations that were measured for the respective protein. A “fast scenario” assumes XIAP
concentration tobeoneS.E. value lower than the average concentrationdetected forXIAPandall other proteins oneS.E. valuehigher than themeasured concentrations.To extend
the range of acceptable parameter sets, the S.D. was used instead of the S.E. for the parameter screening in the optimization workflow (Figs. 5 and 6).
Scenario
Proteins
Anti-apoptotic (XIAP)
Pro-apoptotic
Procaspase-3 Procaspase-9 Smac Apaf-1
Slow Average S.E. (S.D.) Average S.E. (S.D.) Average S.E. (S.D.) Average S.E. (S.D.) Average S.E. (S.D.)
Average Average Average Average Average Average
Fast Average S.E. (S.D.) Average S.E. (S.D.) Average S.E. (S.D.) Average S.E. (S.D.) Average S.E. (S.D.)
Systems Analysis of Apoptosis Heterogeneity after MOMP
41548 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 49•NOVEMBER 30, 2012
 at R
oyal College of Surgeons in Ireland on M
ay 23, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
previously (25). Briefly, pairs of two parameters were varied,
and changes in model predictions (amount of substrate cleav-
age over time) were assessed. Results of pairwise variations
were assigned asmatrix elements, and principal components of
this matrix were calculated. The principal components associ-
ated with the highest eigenvalues were regarded as parameter
combinations with the highest influence on the model output.
Only the first principal component was evaluated due to its
dominant influence on substrate cleavage (85% explained vari-
ance where all cells and scenarios were pooled). Parameters
were ranked according to the highest influence on this first
principal component. The 10 parameters with highest rank
were defined as parameter set C (“cooperative”; Table 2).
Workflow to Assess the Robustness of Apoptosis against
Parameter Variations—A workflow for testing the robustness
of apoptosis execution kinetics against variations of kinetic
parameters was developed (Fig. 5A). The workflow employed
parameter sets I and C, which were identified as those param-
eters whose variations had, either alone or in combination, the
most decisive influence on the model output (caspase-depen-
dent DEVD-FRET substrate cleavage over time) for HCT-116,
DLD-1, and HeLa cells in combination. Values of these param-
eters were assumed to vary within a biologically realistic range,
obtained from concurring values described in literature (sup-
plemental Table 2). Several sets of parameter values were
assigned to each parameter set. Values were taken from the
above realistic range using an equidistant set (brute force
screening) or randomly drawn from a uniform distribution
(Monte Carlo screening).
A set of parameter values was assumed to be realistic when
the APOPTO-CELL prediction of substrate cleavage over time
fulfilled two experimentally motivated filter criteria. A first fil-
ter criterion (criterion “PX” for “protein expression”; Fig. 5B)
was assumed to reflect the experimental fact that HeLa cells
with about 4.5-fold expression of XIAP levels (HeLa XIAPAdv
cells) did not show full cleavage of their substrate upon apopto-
sis, whereas HeLa wild type cells did (17). Therefore, a series of
calculations for HeLa cells was performed with varied initial
levels of XIAP. It was required that the model predict at least
95% of the cell substrate after 300 min for cells with less than
1.6-fold overexpression (0.1 M) of XIAP. Likewise, it was
required that more than 50% of cell substrate remain present
when XIAP was expressed 7.9 times or higher (0.5 M). Param-
eter value sets where the predicted substrate cleavage did not
fulfill this criterion were immediately discarded.
A second filter criterion (criterion “S80,” for “time to 80%
substrate cleavage”; Fig. 5C) was employed to check whether
the predicted apoptosis execution kinetics for DLD-1, HCT-
116, and HeLa cells were in a range reasonably close to the
experimentally detected values. Uncertainties of predictions
imposed by experimental variations in input proteins were fur-
ther taken into account. Fulfillment of the criterion required
that the time t80fast (time point of 80% substrate cleavage for the
“fast scenario”) was predicted to be earlier and the time t80slow for
the “slow scenario” to be later than the time where 80% FRET
substrate was observed to be cleaved experimentally (Table 1).
The compliance to this criterion was first checked for all inves-
tigated cells (DLD-1, HCT-116, and HeLa) individually. Subse-
quently, it was checked what parameter value sets fulfilled this
criterion for all combinations of two or for all three cell types.
Brute force screening was performed on the five most influ-
ential parameters of parameter set C. For each of those five
parameters, 10 equidistant values were taken over the entire
parameter range and permuted, resulting in 100,000 parameter
value sets and, thus, as many test calculations.
Monte Carlo screening was performed for the five and ten
most influential parameters of parameter set I and parameter
set C. Therefore, stochastically selected parameter values were
used and taken from a uniform distribution of the five-dimen-
sional or 10-dimensional parameter space (Table 2). ForMonte
Carlo simulations with five parameters, calculations with either
1050 or 100,000 parameter value combinationswere performed
to confirm thatMonte Carlo screening with less density of even
a 1050-parameter value setwould lead to acceptable results. For
Monte Carlo screening of 10 parameters, 1,050,000 parameter
value sets were used.
Assessment of Screening Results to Quantify Alternative
APOPTO-CELL Parameterizations—For each screening
attempt (i.e. brute force screening with five parameters and
Monte Carlo screening with five and 10 parameters), sets of
parameter values were obtained such that they fulfilled both
filter criteria defined above. These resulting sets of parameter
valueswere assessedaccording tohowwell thepredicted substrate
cleavage (here denoted as calculated FRET trace, FRETcalc) agreed
withexperimental FRETtraces (FRETexp). For this assessment, the
followinggoodnessof fit functionwasused,whichwasadjusted for
the degrees of freedom,
Radj
2 
 1

i 1
n
FRETexpti FRET
calcti
2

i 1
n
FRETexptimeanFRET
expt2

n 1
nm 1
(Eq. 2)
TABLE 2
List of selected kinetic parameters of the model
Parameters identified as most decisive regulators of model output (predicted FRET
substrate cleavage over time) by individual assessment (parameter set I) and pair-
wise assessment (parameter set C). ID, parameter ID as defined in supplemental
Table I. Description, short description of biochemical role of parameter. Set, param-
eter set in which this parameter is used. Further details of the mechanistic role of
these parameters (as defined by model equations) can be found in supplemental
Table I.
ID Description Set
2 XIAP production rate I, C
3 Caspase-9 (p35/p12) activity (cleavage of procaspase-3) I, C
5 Caspase-9 (p35/p10) activity (cleavage of procaspase-3) I, C
7 Inhibition of caspase-3 by XIAP I, C
8 Dissociation of XIAPcaspase-3 complex I
23 Release of active caspase-9 from XIAP I, C
25 Inhibition of caspase-9 by XIAP C
32 Dissociation of XIAP-Smac complex I
36 Competitive association of Smac with XIAPcaspase-3
complex
I
54 Degradation of XIAPcaspase-9 complex (p35/p10) I, C
67 Substrate cleavage by caspase-3 I, C
68 Speed of apoptosome formation (caspase-9 activation) C
69 Smac release from mitochondria C
Systems Analysis of Apoptosis Heterogeneity after MOMP
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In Equation 2, n denotes the number (n
 101) of time points
(ti), andm is the number of screening parameters (m
 5 or 10,
respectively). All Radj2 values belonging to a particular screening
and to a particular cell line (HCT-116, DLD-1, and HeLa cells)
were sorted in descending order. Then all Radj2 values were
scaled to the range from1 (value set with bestmatch) to 0 (value
set with least match). For each screening, Radj2 values for HeLa,
HCT-116, and DLD-1 were added. The 10 sets of parameter
values with the highest total values (Radj2 over these three cells)
were selected. With all different screening methods, different
parameter sets, and different subsets of influential parameters,
60 sets of parameter values were used (see “Results” for the
chosen combinations).
RESULTS
Execution of Caspase-dependent Apoptosis after MOMP Is
Impaired in HCT-116 Smac/ and LoVo Cells—MOMP is
often regarded as a point of no return in programmed cell
death.However, evidencehasbeen foundthatproteins involved in
apoptotic processes subsequent to MOMP are also predictive
markers of outcome of chemotherapy treatment (26–29). These
findings suggest that deregulation of these proteins may impact
the efficiency of chemotherapeutically induced apoptosis. We
thereforehypothesized that in somecell systems, apoptosis signal-
ing subsequent toMOMP can be impaired.
Previous single cell microscopy experiments of our group
demonstrated that HeLa cervical carcinoma cells, MCF-7
breast cancer cells expressing caspase-3, and the colorectal can-
cer cell lines DLD-1 and HCT-116 as well as their XIAP-defi-
cient clonal lines DLD-1 XIAP0/ and HCT-116 XIAP0/
showed rapid cleavage of cellular substrate afterMOMP (17, 20,
22, 23). In contrast, HeLa cells that were infected to overexpress
the anti-apoptotic protein XIAP (HeLa XIAPAdv) showed slow
effector caspase activation that led to submaximal cleavage of
cellular substrate (17). We therefore sought further evidence
for whether two types of responses in cancer cell lines after
MOMP exist that can be associated with either rapid and com-
plete or delayed and/or submaximal (i.e. impaired) cleavage of
cellular substrate.
To investigate this, we first exposed HT-29 human colon
adenocarcinoma cells to a 3 M concentration of the broad
spectrum kinase inhibitor STS, a stimulus that induces cell
death through the mitochondrial apoptosis pathway. From the
cells analyzed, MOMP was observed in 35 of 42 cells (83%; n

2 independent experiments), as indicated bymitochondrial flu-
orescence reduction of the cationic dye TMRM. Moreover,
HT-29 cells that underwentMOMPalso showed rapid and pro-
nounced caspase activation, as indicated by the cleavage of the
caspase-sensitive DEVD-FRET substrate (see Fig. 1A for two
typical cells). In particular, from the 35 cells showing MOMP,
31 showed onset of FRET disruption, indicating the beginning
of caspase-induced substrate cleavage. Furthermore, 29 of
those 35 cells showing MOMP also reached a plateau in the
FRET response, indicating that this DEVD-FRET substrate
cleavage was complete. Finally, onset of FRET disruption was
already observed 5 3 min (mean S.E.) after MOMP (Fig. 1,
E and F), and complete cleavage was reached 26 min later
(median, with interquartile range 14–30min). Due to the rapid
kinetics of FRET substrate cleavage and the large amount of
cells that underwent robust FRET disruption after MOMP, we
denoted HT-29 and other cell lines showing these features as
“post-MOMP responder cell lines.”
We next wondered whether the absence of a pro-apoptotic
protein, such as Smac, which acts as enhancer of caspase activ-
ity, may impair caspase-dependent apoptosis. Using the same
treatment protocol as in this study, we previously demon-
strated that parental HCT-116 colorectal cancer cells under-
went fairly rapid apoptosis (20). We therefore performed the
same experiments in the Smac-deficient HCT-116 clone
(HCT-116 Smac/). As result, 34 of 41 analyzed cells (n 
 2
experiments) still underwentMOMP, yet fewer cells than in the
HT-29 cell line that underwent MOMP also showed onset of
FRET cleavage (76%; Fig. 1, B (for a typical cell) and D for all
analyzed cells). Even fewer cells that underwent MOMP
reached a plateau in the FRET signal (65%, Fig. 1D), which
would have indicated complete cleavage of DEVD-FRET sub-
strate during the time frame investigated here. Most strikingly,
on average, onset (165 151 min) and duration (79 min; inter-
quartile range 44–122 min) of DEVD-FRET substrate cleavage
was significantly delayed compared with HT-29 cells (Fig. 1F).
As an aside,wenote that themarkedly slower apoptosis kinetics in
HCT-116 Smac/ as opposed to parental HCT-116 calls cannot
be explained by differences in expressions of BCL-2 family pro-
teins because both clones had similar expression levels of these
proteins comparedwith thepost-MOMPresponder cell lineHeLa
(data not shown). To this end, BCL-2proteins have been shown to
be dispensable for processes afterMOMP (1).
We finally sought a cell line that shows impairment of
DEVD-FRET substrate cleavage but is not known to have any
deficiencies or deregulations in proteins responsible for regu-
lating apoptosis subsequent to MOMP. We speculated that
LoVo adenocarcinoma cells may be such a cell line, supported
by the fact that in-house flow cytometry proved them to be
remarkably resistant to genotoxic stress.4 Indeed, repeating the
above single cellmicroscopy experiments in LoVo cells demon-
strated that from those cells that underwent MOMP (54 of 67
analyzed cells), less thanhalf (25 of 54 cells) showed a detectable
onset of DEVD-FRET substrate cleavage (Fig. 1, C (for typical
cells with delayed cleavage and for such cells showing no
DEVD-FRET cleavage) and D (for cell populations)), and even
fewer cells (20 cells, 37%) reached a plateau, indicating that in
the remaining 63% of cells, only little or no FRET substrate was
cleaved. This was also corroborated by acceptor photobleach-
ing, which demonstrated incomplete substrate cleavage in
LoVo cells subsequent to MOMP (data not shown). Similar to
HCT-116 Smac/ cells, the onset of caspase activation was
late (onset 209 196 min after MOMP; Fig. 1F), and substrate
was cleaved slowly (80min, interquartile range 26–94min; Fig.
1F). We concluded that, similar to the previously characterized
XIAP-overexpressing HeLa XIAPAdv cells (17), HCT-116
Smac/ and LoVo cells also showed a significantly delayed
caspase activation, a high cell-to-cell variability in the kinetics
4 AndreasU. Lindner, C.G. Concannon,G. J. Boukes,M.D.Cannon, F. Llambi,D.
Ryan, K. Boland, J. Kehoe, D. A. McNamara, F. Murray, E. W. Kay, S. Hector,
D. R. Green, H. J. Huber, and J. H. M. Prehn, submitted for publication.
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of FRET cleavage, and often no FRET cleavage at all after
MOMP. We therefore defined such cell lines with delayed
and/or lack of FRET substrate cleavage as “post-MOMP-im-
paired responder cell lines.”
Systems Modeling Explains Impairment of Apoptosis Execu-
tion after MOMP—Delayed or blocked caspase activation can
transform cells into a potentially malignant state or make them
resistant to chemotherapeutically induced apoptosis (1, 2, 30).
Indeed, once caspase activation is inhibited, cells have been
shown to be able to recover fromMOMP (15, 31–33). A correct
classification as to whether or not a cell line is a potential post-
MOMP-impaired responder cell line may therefore be a valua-
ble parameter in assessing the success of chemotherapeutic
treatments that induce the mitochondrial apoptosis pathway.
We therefore investigated whether our model APOPTO-CELL
was able to correctly distinguish between responder and
FIGURE 1. Two classes of response to apoptosis execution subsequent to MOMP. A–C, representative single cell traces of the post-MOMP responder cell
line HT-29 (A) and the post-MOMP-impaired responder cell lines HCT-116 Smac/ (B) and LoVo (C) after exposure to 3 M STS. For each cell, time series of
DEVD-FRET substrate (CFP/FRET ratio) andmitochondrial polarizationmeasuredby TMRMare given. The left panels show time series of single cell fluorescence
images, whereas the right panels show quantifications of these values for the representative cells. Onset of loss of TMRM was regarded as the time point of
MOMP and indicated by a black arrow. A, HT-29 cells showed rapid DEVD-FRET substrate cleavage after MOMP. B, typical HCT-116 Smac/ cells showed a
significant delay. C, a high amount of LoVo cells showed a delay and often noDEVD-FRET substrate cleavage at all. Cells showing noDEVD-FRET cleavage after
MOMPwere alive at termination of the experiment or underwent necrotic cell death (time point 929). D, from those HT-29, HCT-116 Smac/, and LoVo cells
that underwent MOMP, the fraction of cells that showed onset (left column) and the fraction that showed robust DEVD-FRET substrate cleavage (indicated by
a plateau; left column) are depicted.Heatmap coloring from dark green to red indicates decrease in the amounts of cells. E and F, time of onset (E) and duration
(F) of DEVD-FRET substrate cleavage in HT-29, HCT-116 Smac/, and LoVo cells indicates a significantly longer duration and a higher cell to cell variability in
the latter two cell lines (*, p 0.001, analysis of variance followed by pairwise t test for onset; p 0.001, Kruskal-Wallis followed by pairwiseMann-Whitney for
duration). a.u., arbitrary units. Bars showing meanS.E. (E) and median with upper quartile (F).
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impaired responder cell lines. Because APOPTO-CELL
required absolute concentrations of the proteins APAF-1,
Smac, procaspase-3/-9, and XIAP as input, we determined
these concentrations by quantitative Western blots using pre-
viously determined values in HeLa cells as a standard (Fig. 2,
A–E, n 
 3 experiments, mean  S.E.). To allow us to model
cell-to-cell variability within populations of each cell line, we
further included the S.E. of the detected protein levels into our
analysis. We constructed, for each cell line, three different sets
of input protein data that are associated with different speeds
and efficiency of apoptosis execution (Table 1; “slow scenario,”
“average scenario,” and “fast scenario”; see “Experimental Pro-
FIGURE 2. APOPTO-CELL explains impairment of apoptosis execution subsequent to MOMP. A–E, procaspase-3 (A), APAF-1 (B), XIAP (C), Smac (D), and
procaspase-9 (E) concentrations were quantified in HCT-116, DLD-1, LoVo, MCF-7/C3, and HT-29 cells. HeLa cells whose absolute concentrations were quan-
tified previously (17) were used as reference. Error bars, S.E. of three experiments. F–K, APOPTO-CELL predictions for kinetics of substrate cleavage in HT-29-
(F), HCT-116- (G), HeLa- (H), DLD-1- (I), DLD-1 XIAP0/- (J), HCT-116 XIAP0/- (K), MCF-7/C3- (L), LoVo- (M), HCT-116 Smac/- (N), and XIAP-overexpressing
(O) HeLa XIAPAdv cells using above protein concentrations as input. Dashed lines indicate the predicted kinetics of substrate cleavage over time after MOMP,
calculated fromabove averageprotein concentrations. Thegray area indicates plausible kinetics for cells of the entire populationof the respective cell line (see
“Experimental Procedures”). F–L, post-MOMP responder cell lineswere classifiedby themodel to have rapid kinetics of substrate cleavage in a typical cell of the
population (dashed line), a rather synchronized response in cleavage over the population (smaller gray area), and a complete substrate cleavage in almost all
cells (80% after 300 min). Predictions aligned well with the fast and robust apoptosis execution kinetics for HT-29 cells in Fig. 1A and with previous
measurements in the other cells where apoptosis execution was determined to require less than 80 min (17, 20, 23)). M–O, experimentally classified post-
MOMP-impaired responder cell lines were correctly predicted to have slow kinetics of substrate cleavage in an average cell of a population (dashed line) and a
low amount of substrate cleavage after 300 min, consistent with the reduced amount of cells showing robust DEVD-FRET substrate cleavage after MOMP.
Kinetics of substrate cleavage were predicted to be highly heterogeneous over the population consistent with the findings in Fig. 1, E and F, and Ref. 17.
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cedures”). Using APOPTO-CELL, we calculated the amount of
substrate cleavage that is cleaved over time. We assumed that
any realistic prediction of substrate cleavage within a popula-
tion of a particular cell line must lie in the range between the
slow and fast scenario (gray areas in Fig. 2, F–O, average sce-
nario indicated by a dashed line).
By comparison with experimental data, we found that
APOPTO-CELL correctly classified HT-29 cells as a post-
MOMP responder cell line. This was indicated by the fact that
the calculated kinetics of substrate cleavage, based on the aver-
age protein concentration for this cell line, were found to be fast
(Fig. 2F, dashed line), that population-based variability was
modest (small gray area), and that after 300min, 80–100% of
the substrate was cleaved. By similar means, APOPTO-CELL
correctly classified HCT-116 WT, HeLa WT, DLD-1 WT,
DLD-1XIAP0/, HCT-116 XIAP0/, and MCF-7/C3 cells as
responder cell lines (Fig. 2, H–L). This finding was consistent
with previously published single cell data demonstrating that
caspase activation was fast and robust in these cells (17, 20, 23).
Further, these calculations confirmed experimental findings
that lack of XIAP accelerated apoptosis execution (20).
In contrast, LoVo, HCT-116 Smac/, and HeLa XIAPAdv
cells were correctly classified as post-MOMP-impaired
responder cells. In particular, APOPTO-CELL predicted a high
cell-to-cell variability in the apoptotic kinetics, as indicated by
the size of the gray area in all of these cell lines (Fig. 2, M–O).
This mirrored the experimental cell-to-cell variability in onset
andduration ofDEVD-FRET substrate cleavage (Fig. 1,E andF)
(17). In further agreement with experimental data presented
here and in Ref. 17, the DEVD-FRET substrate cleavage based
on the average protein concentrations was correctly predicted
to be slow and to be incomplete after 300 min (dashed lines in
Fig. 2, M–O, substrate cleavage 10% for LoVo, 50% for
HCT-116 Smac/, and25% for HeLa XIAPAdv).
After having successfully employed APOPTO-CELL to sep-
arate post-MOMP responder and non-responder cell lines, we
finally wanted to investigate how well APOPTO-CELL resem-
bled the onset and duration of FRET cleavage in the investi-
gated cell lines. As can be seen in Fig. 3A, agreement between
predicted and experimental onset was highly statistically signif-
icant (p
 0.002, 
 0.852 Pearson correlation). Predicted and
experimentally determined duration of FRET cleavage (5–95%;
only cell lines were shownwhere at least 95% substrate cleavage
was predicted)matchedwell forHeLa andHT-29 cells aswell as
for DLD-1 cells, HCT-116 WT cells, and their XIAP-deficient
clones. For MCF-7/C3 cells, we observed deviations (Fig. 3B),
suggesting that additional molecular mechanisms may be rele-
vant in this cell line that may have been underestimated by
APOPTO-CELL. Nevertheless, the good agreement of apopto-
sis kinetics in the other cell lines advocates for further employ-
ing APOPTO-CELL for amore detailed investigation ofmolec-
ular mechanisms of apoptosis as performed below.
Apoptosis Kinetics Are Influenced by Different Protein Inter-
actions in HeLa, HCT-116, and DLD-1 Cells—Above, we dem-
onstrated that APOPTO-CELL can distinguish between two
classes of responder cells subsequent to MOMP and compared
experimentally determined and predicted cleavage of FRET
substrate. Encouraged by the agreement between model pre-
dictions and experiments, we focused in the remainder of
this study on howAPOPTO-CELLmay be employed to study
molecular mechanisms of apoptosis execution and heteroge-
neity between cells within a population of one cell line and
between cell lines. We focused on HeLa, HCT-116, and
DLD-1 cells because APOPTO-CELL not only correctly clas-
sified them as post-MOMP responder cells but also fairly
accurately predicted the experimental kinetics of FRET
onset and duration.
We first employed APOPTO-CELL to demonstrate how cell
line-specific protein profiles (Fig. 2, A–E) give rise to a differ-
ential importance of themolecular interactions in the apoptosis
pathway subsequent to MOMP in each cell line. In the model,
the strength of each molecular (protein) interaction is defined
by kinetic parameters. Changing their values and assessing the
influences on apoptosis kinetics may therefore assess how
robust apoptosis would be when these interactions are modu-
lated by mutations or pharmacological intervention.
We used individual parameter assessment as described
under “Experimental Procedures” to vary all 69 parameters of
APOPTO-CELL between 8-fold down- and up-regulation. We
then assessed how the time point where 80% cell substrate was
FIGURE 3. APOPTO-CELL resembles experimental onset and kinetics of apoptosis execution subsequent to MOMP. A, comparison of predicted and
experimental onset of DEVD-FRET substrate cleavage after MOMP for 10 cell lines. Onset in APOPTO-CELLwas defined as when 5%of substrate is predicted to
be cleaved, whereas experimental onset was determined visually from the traces. Results aligned along the identity line, and correlation was significant
(Pearson correlation 
 0.860, p
 0.001). B, comparison of predicted and experimental duration of DEVD-FRET substrate cleavage after MOMP aligned for
most cell lineswith sufficient accuracy.Only cell lines thatwerepredicted to reach95%were included.Duration in themodelwas specified as the timebetween
5 and 95% predicted substrate cleavage.
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predicted to be cleaved (t80) changes upon parameter variation.
The most influential kinetic parameters were assumed to be
those thatmost altered apoptosis execution kinetics. Results for
the above cell lines are shown in Fig. 4,A–C, (using the “average
scenario”). Parameters were indexed by number, ranked
according to the difference of t80 between maximum and min-
imum values after down- and up-regulation, and associated
with protein interactions according to supplemental Table 1. In
all three cell lines, parameter 3, which described caspase-9
activity (p35/p12 fraction cleaving procaspase-3 (33, 34)), was
most important. In HCT-116 and DLD-1 cells, the speed of
XIAP production and the degradation of XIAPcaspase-9 com-
plex (parameters 2 and 54 (35, 36)) were further important reg-
ulators of apoptosis execution kinetics. In turn, the substrate
cleavage by active caspase-3 and the speed of apoptosome for-
mation (parameters 68 and 69 (37, 38)) weremore important in
HeLa cells. Together, these systems modeling data suggested
that in different cell lines, different protein interactions may be
influential for apoptosis execution.
We alternatively employed a method to investigate simultane-
ous variation of kinetic parameters. Such a method was proposed
recently (25). It assumes pairwise variations of model parameters
while studying the influence on apoptosis kinetics. Strikingly,
resultsof thismethodagreedwith the individualparameter assess-
ment above inputting emphasis on caspase-9 activity, the speedof
XIAP production, and the degradation of XIAPcaspase-9 com-
plex with respect to apoptosis regulation. Similar to the individual
parameter assessment, it draws attention to the cell-specific
importance of different protein interactions (Table 2).
A Workflow to Assess the Robustness of Apoptosis Execution
against Changes of Kinetic Parameters—Kinetic parameters
depend on cell-specific properties, such as cellular pH or pro-
tein motility (39). We therefore first wanted to employ systems
modeling to investigate how robust apoptosis execution kinet-
ics were when kinetic parameters changed over a biologically
realistic range. Second, we asked whether or not we could find
sets of parameter values that improved the overall predictability
of APOPTO-CELL for all cell lines.
To address both questions, we constructed a workflow (Fig.
5A). Because it would have required overly high computational
costs to assess variations of all 69 kinetic parameters at the same
time, we first sought a way to assess what kinetic parameters
have the most decisive influence on apoptosis kinetics. We
therefore employed both parameter assessment methods
described above and assessed the cumulative changes in apo-
ptosis kinetics for all three cell lines under investigation. Using
the individual parameter assessment method, we obtained
those parameters that exercised the highest influence on apo-
ptosis execution kinetics when they were varied independently
over a larger, 8-fold range (set I in Table 2). In contrast, by using
the parameter cooperation assessment method, we identified a
parameter set to assess the robustness of apoptosis kinetics
against variations in those parameters that in combinationwith
each other have the most decisive influence on apoptosis exe-
cution kinetics (set C in Table 2).
After identifying two partly overlapping sets of parameters
that most decisively influenced apoptosis kinetics (Table 2), we
looked for an appropriate range of associated values by scan-
ning reports where those parameters were experimentally
determined andwhich varied over a certain range betweenpub-
lications. The obtained values were sampled in sets (several sets
of values belonging to each parameter set I or C; i.e. sets of sets),
and each set was included in APOPTO-CELL. The resulting
predictions of apoptosis execution kinetics were verified using
two filter criteria for each cell. As a first criterion (criterion PX,
for protein expression criterion), we required that for XIAP-
overexpressing HeLa cells (HeLa XIAPAdv), the predicted sub-
strate cleavage for cells after 300 min (0.5 M XIAP) was less
than 50% (Fig. 5B). This criterion was motivated by previous
findings in our laboratory that FRET substrate in HeLa
XIAPAdv cellswasnot entirely cleaved (17). Second, for eachof the
three cell lines, DLD-1 WT, HCT-116 WT, and HeLa WT, we
required that the experimental time point where 80% substrate
was cleaved occurred later than the predicted time point for 80%
substrate cleavage for the fast scenario and earlier than the pre-
dicted time point for 80% substrate cleavage for the slow scenario
(criterion S80, for 80% substrate cleavage; Fig. 5C). In conclusion,
we devised a workflow that assessed the robustness of model pre-
dictions against changes of themost important kinetic parameters
under constraints obtained from experimental single cell data.
Prediction of Apoptosis Execution Kinetics Is Robust against
Changes in Kinetic Parameters in HeLa andHCT-116 Cells and
More Sensitive inDLD-1Cells—Having established aworkflow,
we validated the APOPTO-CELL prediction for several sets of
values that belonged to each parameter set and that were cho-
sen from a biologically realistically range screened from the
literature (supplemental Table 2). At first, we took sample val-
FIGURE 4. Individual parameter assessment inDLD-1, HCT-116, andHeLa
cell lines. A–C, bars show the predicted time from MOMP to 80% caspase-3
substrate cleavage based on average protein concentrations andup to 8-fold
down- and up-regulation of individual kinetic parameters. The 10 kinetic
parameters that resulted in the strongest change in model predictions
between 8-fold down- and up-regulation are depicted. Parameters are asso-
ciated with protein interactions and indicated by their number according to
supplemental Table 1. Caspase-9 (p35/p12) activity (cleaving procaspase-3)
was the most decisive regulator of apoptosis execution kinetics in all cells
(parameter 3). Cleavage of cell substrate by caspase-3 and speed of the apo-
ptosome formation (parameters 68 and 69) were important in HeLa cells (A),
whereas XIAP production and the derepression of apoptosome blocking by
XIAP (parameters 2 and54)were important inHCT-116 (B) andDLD-1 cells (C).
Systems Analysis of Apoptosis Heterogeneity after MOMP
41554 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 49•NOVEMBER 30, 2012
 at R
oyal College of Surgeons in Ireland on M
ay 23, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ues for each parameter obtained from dividing the entire range
of values into uniformly distributed steps (brute force screen-
ing). However, assuming 10 parameters and 10 values/parame-
ter led to 1010 combinations, which would have led to an esti-
mated computation effort of 200,000 days (assuming 1.7 s per
calculation) on a single core CPU. We therefore performed
brute force screening for only the five most influential param-
eters of set C (100,000 combinations of parameters, 48-h calcu-
lation time). This results in 84% of all sets of parameter values
fulfilling criterion PX. We then checked whether other cells or
cell combinations also fulfilled (the HCT-116-, DLD-1-, and
HeLa-specific) criterion S80 in addition to criterion PX. Inter-
estingly, 81% of all sets passed both criteria for HCT-116 and
HeLa cells (Venn diagram in Fig. 6A). In contrast, only 24%
of all samples fulfilled both criteria for DLD-1 cells, the same
24% for DLD-1 and HCT-116 cells in combination, and only
22% were found to be valid for HeLa and DLD-1 simultane-
ously. As a consequence, a low rate of only 22% fulfilled both
criteria for all cell lines.
We next evaluated whether brute force screening could be
replaced by using screenings of stochastic samples of parameter
value sets (“Monte Carlo screening”). In particular, we investi-
gated whether or not stochastic sampling allows reducing the
sampling size per parameter and therefore allows more param-
eters to be screened.We first appliedMonte Carlo screening to
samples of parameter values for the same five parameters of set
C as for brute force screening. Using the same numbers of sam-
ple sets (100,000), a similar percentage of sets fulfilled both
filter criteria for all cells (24%). As before, a high number of sets
passed both criteria for HCT-116 andHeLa, whereas only a few
sets passed both criteria when DLD-1 cells were taken into
account in any combination with the other cell lines (Fig. 6B).
Due to the high numbers of screenings and the low numbers of
parameters, the good agreement between brute force screening
and Monte Carlo screening was not unexpected. However, the
agreement between both screening types was still good when
we reduced the number of Monte Carlo samples to 1050 (Fig.
6C). This is interesting because only 4 values/parameter
range (45
 1024)were tested. This agreement therefore cannot
be explained only by stochasticity and suggests that these five
parameters (and generally all parameters in this model) do not
represent separate degrees of freedom.
The fact that only 4 values/parameter were enough to achieve
an acceptable Monte Carlo screening allowed us to extend the
screening to 10 parameters, which in brute force screening would
have exceededany reasonable computation time.ApplyingMonte
Carlo screening to the 10 parameters of parameter setC andusing
1,050,000 (i.e. 4 values/parameter, 410 
 1,048,576), we ascer-
tained that 15%of all parameter value sets fulfilled the filter criteria
for all cell lines (Fig. 6D). Again, only comparably few parameter
value sets fulfilled them for DLD-1 cells, irrespective of whether
DLD-1 cellswere tested alone (23%)or in combinationwithHCT-
116 (23%) or HeLa cells (15%).
We then asked whether this dissimilarity of DLD-1 cells
compared with HCT-116 and HeLa cells was due to the partic-
ular choice of the parameter set C. We therefore repeated
Monte Carlo screening using parameter set I with five and 10
parameters (1050 and 1,050,000 screened value sets, respec-
tively). Also here, the filter criteria were only fulfilled for 20% of
sets (24%) of parameter values when criterion S80 was applied
only to DLD-1 cells. In the screening of five parameters, the
number of valid sets was not detectably decreased when this
criterion was imposed on all cells (Fig. 6E) but was more pro-
FIGURE 5. A workflow to assess the robustness of apoptosis execution
and to calibrate systems models. A, a workflow was devised that allowed
validation of the robustness of apoptosis execution kinetics against changes
in values of kinetic parameters over a biologically justified range (supplemen-
tal Table 3). The workflow was confined to study changes in values for the
parameter sets I and C according to Table 2. Sets of values that correspond to
both parameter sets were obtained using either brute force or Monte Carlo
screening. A set of five (or 10) parameter valueswas considered to explain the
experimental apoptosis execution kinetics when two filter criteria were met.
These criteria aim to filter thoseparameter value sets forwhich thealternative
APOPTO-CELL gives reasonable predictions for experimental apoptosis exe-
cution kinetics in HCT-116, DLD-1, and HeLa cells and in XIAP-overexpressing
HeLa cells under uncertainties in input protein levels. B and C, detailed filter
criteria are given. B, a first filter criterion (criterion PX) required that HeLa cells
with XIAP less than 0.1 M show full substrate cleavage, whereas HeLa
cells with more than 0.5 M show substrate cleavage less than 50%, consist-
ent with our experimental findings for HeLa XIAPAdv cells (17). C, a second
filter criterion (criterion S80) required that the time point where 80% of cell
substrate was experimentally determined to be cleaved be located between
the predicted time points for 80% substrate cleavage of the fast scenario and
for 80% substrate cleavage of the slow scenario of apoptosis (see Table 1).
Criterion S80 was specifically tested for HeLa, HCT-116, and DLD-1 cells.
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nouncedly decreasedwhen 10 parameters were screened (9% of
all value sets) (Fig. 6F). Thus, similar to set C, the DLD-1 cell
line posed the most severe restriction to fulfill filter criterion
S80, whereas HCT-116 and HeLa cells showed more tolerance
against parameter variation. These results suggest that the lat-
ter two cell lines aremore robust in apoptosis execution against
variations in enzyme kinetics caused by fluctuations in pH or
temperature.
Using different sets of parameter values to parameterize
APOPTO-CELL as obtained from the different screening
methods, we finally investigated whether any of these alterna-
tive parameterizations would better predict experimentally
observed apoptosis execution kinetics.We therefore calculated
a residual function R2 and ranked the parameter sets according
to how well they describe the experimental FRET traces for the
three cell lines under investigation (see “Experimental Proce-
FIGURE 6. Brute force andMonte Carlo screening determined apoptosis execution kinetics in HCT-116 and HeLa cells as robust and in DLD-1 cells as
more sensitive to changes of kinetic parameters. A–F, the workflow of Fig. 5 was applied for parameter sets I and C (Table 2), choosing kinetic parameters
either from a uniform discrete grid (brute force; A) or stochastically drawn from a unique distribution (Monte Carlo; B–F) of the value range of supplemental
Table 2. Screening was performed for different parameter sets and different numbers of sets of values. Results of screenings are given by Venn diagrams.
A, brute force screening of 100,000 variations of the five most influential kinetic parameters from set C. Of the screened sets, 22% result in acceptable model
predictions of apoptosis execution kinetics in all three cell lines. B, Monte Carlo screening of 100,000 variations of the five most influential kinetic parameters
from parameter set C leads to a slightly higher amount (24%) of value combinations than brute force screening of the same parameter value range (see A).
C, reducing the screening density to only 1050 variations of the fivemost influential kinetic parameters fromparameter set C leads to similar Venn sets as with
100,000 variations. D, Monte Carlo screening of 1,050,000 variations of the 10 most influential kinetic parameters from parameter set C. E, Monte Carlo
screening of 1050 variations of the fivemost influential kinetic parameters fromparameter set I. F, Monte Carlo screening of 1,050,000 variations of the 10most
influential kinetic parameters from parameter set I. Raw data and results for the average of all screening can be found in supplemental Table 3. G and
H, APOPTO-CELL using alternative parameter values did not improve the agreement between predicted and experimental onset (G) and duration (H) of
DEVD-FRET substrate cleavage. A set of values that passed both filter criteria in the screening of Fig. 5 and that was ranked second best with respect to the
goodness of fit (R2) in the screening of Dwas used (see “Experimental Procedures”).
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dures”). The 10 best parameters for each of the six screenings
were further analyzed.
However, when the predicted single cell traces that emerged
from those 60 sets were visually compared against the experimen-
tal FRET traces, no obvious improvement was observed (results
not shown). Nevertheless, as exemplified by the value set that was
ranked secondbest for the screening inFig. 6D, the requirement to
better describe the duration of experimental DEVD-FRET sub-
strate cleavage as imposed by filter criterion S80 led to slightly
better predictionof duration,which cameat the cost of a deviation
in the prediction of the onset (Fig. 6, G andH). Interestingly, this
improvement in the prediction of the duration was also found for
several of those cells thatwerenot included in the filter criteria and
which therefore served as an independent test set.
DISCUSSION
Apoptosis impairment is amajor factor in cancer cells’ resist-
ance to chemotherapy and in clinical relapse (3). The heteroge-
neity of apoptosis execution between different cancer types and
different patients and within tumor tissue presents a major
obstacle to the provision of efficient treatments (40).We there-
fore employed systems modeling to understand the sources of
heterogeneity and apoptosis impairment in different cancer cell
lines that can arise subsequent to MOMP.
Apoptosis as a Two-step Process Prior and Subsequent to
MOMP—Control points of apoptosis lie prior to and subse-
quent toMOMP (3–5, 26–29). Prior toMOMP, control of apo-
ptosis is governed by the interplay of antagonizing BCL-2
proteins (41). To this end, Letai and co-workers (4, 5) demon-
strated that in situ cancer cells may accumulate tonic pro-apo-
ptotic signals without committingMOMP.Due to having accu-
mulated these stimuli, cancer cells are therefore thought to
becomemore susceptible than non-transformed cells to under-
going MOMP in response to chemotherapeutics, a notion
termed mitochondrial priming. It is important to note that
within the context of their work, a higher susceptibility mani-
fests in the requirement of a lower chemotherapeutic dose to
induce MOMP. In contrast, considering that MOMP is an all-
or-none-process (42), any prior-to-MOMP dose dependence
and any information on mitochondrial priming is unlikely to
influence signaling after MOMP. Therefore, in the context of
our work, the decision as to whether or not apoptosis is exe-
cuted subsequent toMOMP is assumed to be dose-independent.
This decision is therefore considered to depend solely on the
expression levels of the pro- and anti-apoptotic proteins during
apoptosis execution during this phase (17, 43). Due to these spec-
ificities, independent studies of processes prior and subsequent to
MOMP can bring more context-dependent and potentially com-
plementary insights intomechanismsof impairment of cancer cell
death and its therapeutic implications.
Apoptosis Can Be Impaired Subsequent to MOMP and Can
Be Explained by a Systems Analysis Using Absolute Protein
Quantifications—APOPTO-CELL assumesMOMP to be pres-
ent and analyzes the subsequent protein interactions that gov-
ern cell death execution. Our study therefore focused on the
sources of heterogeneity in apoptosis execution subsequent to
MOMP that are introduced in different cancer cell lines and
caused by differential protein expression of the proteins that are
relevant in this downstream pathway. Our experimental and
theoretical results indicate that certain cancer cells can evade
apoptosis by tipping the balance toward higher expressions of
anti-apoptotic proteins and that this evasion can be understood
by a systems analysis. Indeed, loss of APAF-1, overexpression of
XIAP, or down-regulation of Smac, which are likely to attenu-
ate the apoptotic pathway subsequent to MOMP, have been
linked to carcinogenesis and to mediating chemo-resistance
(26–29). To this end,we recently demonstrated thatAPOPTO-
CELL can predict responsiveness to MOMP-inducing, chemo-
therapeutic stimuli using patient-individual protein profiles as
input (17, 43).
Heterogeneity in Apoptosis Signaling Arising from Variations
in Protein Expression within One Cell Line—We have studied
the effect of protein variations within cell populations and
employed APOPTO-CELL to assess the impact of such varia-
tions on the kinetics of apoptosis within different cell lines. A
representative variation of protein levels in a population was
estimated from quantitative Western blotting data. Although
this variability was similar in all cell lines, the predicted apopto-
sis execution kinetics from these data differed. As such, apopto-
sis in HeLa cells was predicted to be more robust against fluc-
tuations in input proteins. In turn, HCT-116 WT cells showed
a higher variability, and LoVo and HCT-116 Smac/ cells
exercised a huge variation in apoptosis kinetics, consistent with
experimental findings. Because heterogeneity in apoptosis can
obstruct the action of chemotherapeutics, APOPTO-CELL
may help to assess how entire populations of different cancer
cell types respond to such stimuli.
Heterogeneity in Apoptosis Signaling Arising from Cell Line-
specific Protein Profiles—We further demonstrated that, due to
different protein expression in different cancer cell lines, differ-
ent protein interactions within the apoptosis pathway may also
be important. This fact becomes importantwhen designing and
applying chemotherapeutic drugs that aim to enhanceor restore
apoptosis by targeting a particular protein or a particular protein
interaction. As such, Smac mimetics (44) enhance apoptosis by
blocking the apoptosis inhibitor XIAP, whereas some compounds
directly activate caspases (45–47), and others target protein deg-
radation (48–50). Because these drugs target specific protein
interactions and because the relative importance of protein inter-
actions may differ between cancer cells, the impact of these drugs
on cancer cell apoptosis may vary between different cell lines, dif-
ferent patients, and different cancers.
Heterogeneity and Robustness of Apoptosis Caused by Fluctu-
ations in Enzymatic Activities—Kinetic parameters are factors
that relate the speed of a chemical reaction to the concentra-
tions of the reaction partners and therefore are a means to
quantify reaction speed of chemical reactions (8). Kinetic
parameters are assumed in APOPTO-CELL to describe enzy-
matic cleavage or enzyme inhibition (17). Although most sys-
tem analyses assumed these parameters to be constant, enzyme
activity is dependent on the cellular environment and influ-
enced by post-translational modifications, temperature, pH,
enzyme motility, and cellular viscosity (39, 51). Thus, kinetic
parameters may either differ between cells (even of the same
population) or differ within one cell depending on the physio-
logical context.We therefore provided a workflow to assess the
Systems Analysis of Apoptosis Heterogeneity after MOMP
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robustness of apoptosis execution kinetics against such changes
in kinetic parameters. Using two independent methods, brute
force andMonte Carlo screening, to screen the effect of kinetic
parameter changes over a range of biologically justified values
from literature, we found that HeLa and HCT-116 cells are
more robust against parameter variations than DLD-1 cells.
This lack of robustness of DLD-1 cells against parameter vari-
ations may indicate that certain protein interactions that may
have been neglected when constructing APOPTO-CELL may
be of particular importance for DLD-1 cells to describe the
exact apoptosis execution kinetics. Indeed, during model con-
struction, we disregarded some players and interactions in
mitochondrial apoptosis for simplicity. For example, we did not
consider the pro-apoptotic protein Omi/HtrA2 (52), which,
like Smac, gets released from the mitochondria and binds to
and antagonizes XIAP.
Optimization of APOPTO-CELL for Uses as a Clinical Tool to
Study Cancer Heterogeneity and Treatment Prognosis—The
APOPTO-CELL prediction of the onset of apoptosis in the
investigated cell lines correlated well with experimental data,
whereas deviations were found when predicting the duration.
We therefore wondered whether a better prediction could be
achieved by optimizing the set of kinetic parameters used in
APOPTO-CELL employing a numerical calibration method
that assumed realistic values for these parameters as input.
Despite the fact that we investigated simultaneous improve-
ment only in DLD-1, HCT-116, and HeLa cells and did not
restrict the search filter too severely, parameter screening and
subsequent optimization did not improve the APOPTO-CELL
prediction of apoptosis execution kinetics for the studied cell
lines. This lack of improvementmay be due to the nonexistence
of a common set of parameter values for these cells. However, it
may also draw attention to necessary refinements of themodel,
such as the inclusion of further protein-protein interactions.
In addition, this study required time-consuming single cell
microscopy measurements to detect the rapid apoptosis kinet-
ics at sufficiently high temporal resolution. Therefore, the study
focused on a reasonable amount of six parental cell lines and
four mutated cell lines to remodel rather than prospectively
predict apoptosis sensitivity. However, to better assess the pre-
dictive power of APOPTO-CELL, additional, prospective vali-
dations to other cell lineswould be necessary.Nevertheless, this
work along with previous studies from our laboratory suggests
that APOPTO-CELL explains cancer cell death or apoptosis
resistance subsequent to MOMP in several cancer cells with
sufficient accuracy (17, 43). In conclusion, our study is the first
systems analysis of heterogeneity and impairment of apoptosis
subsequent to MOMP, emphasizing the importance of this
pathway component in determining the efficacy of apoptosis-
inducing chemotherapy.
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Supplementary Tables 
Supplementary Table I: List of all reactions of the model  
Pseudo-reaction equations as used by APOPTO-CELL and as assembled and published in (13). The 
table denotes the reaction ID (used as parameter ID throughout the text) and the pseudo-reaction that 
relates products of interacting proteins with educts resulting from this interaction. Reactions 1 and 2 
denote protein turnover (production and degradation) of Caspase-3 and XIAP. Reactions 49-61 denote 
degradation of the respective protein. Reactions 68 and 69 describe the input function of formation of 
the apoptosome (induced by cyt-c and requiring procaspase-9 and APAF-1) and release of Smac from 
the mitochondria. Used protein symbols: C3 Procaspase-3; C3a active Caspase-3; C9 Procaspase-9; 
C9a active Caspase-9 (p35/p12); C9H active Caspase-9 (p35/p10); XIAP X-linked Inhibitor of 
Apoptosis Protein; SMAC Secondary Mitochondrial Activator of Apoptosis; BIR12 baculoviral IAP 
repeats 1 and 2 (XIAP fragment); BIR3R baculoviral IAP repeats 3 and RING domain (XIAP 
fragment); cl-C9a fragment (p2) resulting from cleavage of Caspase-9 (p35/p12) to Caspase-9 
(p35/p10); tildes together with square brackets denote protein complexes. For transferring the reaction 
equation into an ODE systems model refer to the supplement of (13). 
 
id reaction kinetic constant 
#1  → C3 0.0039 min-1 
#2  → XIAP 0.0116 min-1 
#3 C9a + C3 → C9a + C3a 6 µM-1 min-1 
#4 C9a + C3a → C9H + C3a 12 µM-1 min-1 
#5 C9H + C3 → C9H + C3a 48 µM-1 min-1 
#6 C3 + C3a → C3a + C3a 2.4 µM-1 min-1 
#7 C3a + XIAP → [XIAP~C3a] 156 µM-1 min-1 
#8 C3a + XIAP← [XIAP~C3a]  0.144 min-1 
#9 C3a + [XIAP~C9a] → [XIAP~C9a~C3a] 156 µM-1 min-1 
#10 C3a + [XIAP~C9a]← [XIAP~C9a~C3a]  0.144 min-1 
#11 C3a + [XIAP~(cl-C9a)] → [[XIAP~(cl-C9a)]~C3a] 156 µM-1 min-1 
#12 C3a + [XIAP~(cl-C9a)]← [[XIAP~(cl-C9a)]~C3a]  0.144 min-1 
#13 C3a + BIR12 → [BIR12~C3a] 156 µM-1 min-1 
#14 C3a + BIR12← [BIR12~C3a]  0.144 min-1 
#15 C3a + XIAP → BIR12 + BIR3R + C3a 12 µM-1 min-1 
#16 C3a + [XIAP~C9a] → BIR12 + [BIR3R~C9a] + C3a 12 µM-1 min-1 
#17 C3a + [XIAP~C3a] → C3a + [BIR12~C3a] + BIR3R 12 µM-1 min-1 
#18 C3a + [XIAP~(cl-C9a)] → C3a + BIR12 + [BIR3R~(cl-C9a)] 12 µM-1 min-1 
#19 C3a + [[XIAP~(cl-C9a)]~C3a] → C3a + [BIR12~C3a] + [BIR3R~(cl-C9a)] 12 µM-1 min-1 
#20 C3a + [XIAP~C9a~C3a] → C3a + [BIR12~C3a] + [BIR3R~C9a] 12 µM-1 min-1 
#21 C3a + [XIAP~2SMAC] → C3a + [BIR12~SMAC] + [BIR3R~SMAC] 12 µM-1 min-1 
#22 C3a + [XIAP~C9a~C3a] → C3a + C9H + [[XIAP~(cl-C9a)]~C3a] 12 µM-1 min-1 
#23 C3a + [XIAP~C9a] → C3a + C9H + [XIAP~(cl-C9a)] 12 µM-1 min-1 
#24 C3a + [BIR3R~C9a] → C3a + [BIR3R~(cl-C9a)] + C9H 12 µM-1 min-1 
id reaction kinetic constant 
#25 C9a + XIAP → [XIAP~C9a] 156 µM-1 min-1 
#26 C9a + XIAP← [XIAP~C9a]  0.144 min-1 
#27 C9a + [XIAP~C3a] → [XIAP~C9a~C3a] 156 µM-1 min-1 
#28 C9a + [XIAP~C3a]← [XIAP~C9a~C3a]  0.144 min-1 
#29 C9a + BIR3R → [BIR3R~C9a] 156 µM-1 min-1 
#30 C9a + BIR3R← [BIR3R~C9a]  0.144 min-1 
#31 XIAP + SMAC + SMAC → [XIAP~2SMAC] 420 µM-2 min-1 
#32 XIAP + SMAC + SMAC← [XIAP~2SMAC]  0.133 min-1 
#33 [XIAP~C9a] + SMAC + SMAC → [XIAP~2SMAC] + C9a 420 µM-2 min-1 
#34 [XIAP~C9a] + SMAC + SMAC← [XIAP~2SMAC] + C9a  0.133 min-1 
#35 [XIAP~C3a] + SMAC + SMAC → [XIAP~2SMAC] + C3a 420 µM-2 min-1 
#36 [XIAP~C3a] + SMAC + SMAC← [XIAP~2SMAC] + C3a  0.133 min-1 
#37 [XIAP~C9a~C3a] + SMAC + SMAC → [XIAP~2SMAC] + C3a + C9H 420 µM-2 min-1 
#38 [XIAP~C9a~C3a] + SMAC + SMAC← [XIAP~2SMAC] + C3a + C9H  0.133 min-1 
#39 BIR12 + SMAC → [BIR12~SMAC] 4.45 µM-1 min-1 
#40 BIR12 + SMAC← [BIR12~SMAC]  31.9 min-1 
#41 BIR3R + SMAC → [BIR3R~SMAC] 0.33 µM-1 min-1 
#42 BIR3R + SMAC← [BIR3R~SMAC]  14.2 min-1 
#43 [BIR12~C3a] + SMAC → [BIR12~SMAC] + C3a 4.45 µM-1 min-1 
#44 [BIR12~C3a] + SMAC← [BIR12~SMAC] + C3a  31.9 min-1 
#45 [BIR3R~C9a] + SMAC → [BIR3R~SMAC] + C9a 0.33 µM-1 min-1 
#46 [BIR3R~C9a] + SMAC← [BIR3R~SMAC] + C9a  14.2 min-1 
#47 [XIAP~(cl-C9a)] + SMAC + SMAC → [XIAP~(cl-C9a)]~ SMAC] 420 µM-2 min-1 
#48 [XIAP~(cl-C9a)] + SMAC + SMAC← [XIAP~(cl-C9a)]~SMAC]  156 µM-1 min-1 
#49 C9H →  0.0058 min-1 
#50 C9a →  0.0058 min-1 
#51 C3a →  0.0058 min-1 
#52 [XIAP~C3a] →  0.0347 min-1 
#53 [XIAP~C9a~C3a] →  0.0347 min-1 
#54 [XIAP~C9a] →  0.0347 min-1 
#55 [XIAP~(cl-C9a)] →  0.0058 min-1 
#56  [[XIAP~(cl-C9a)]~C3a] →  0.0347 min-1 
#57 [XIAP~(cl-C9a)]~SMAC] →  0.0347 min-1 
#58 [XIAP~2SMAC] →  0.0347 min-1 
#59 BIR12 →  0.0058 min-1 
#60 BIR3R →  0.0347 min-1 
#61 [BIR12~SMAC] →  0.0058 min-1 
#62 [BIR3R~SMAC] →  0.0347 min-1 
#63 [BIR12~C3a] →  0.0058 min-1 
#64 [BIR3R~C9a] →  0.0058 min-1 
#65 [BIR3R~(cl-C9a)] →  0.0347 min-1 
#66 SMAC →  0.0058 min-1 
#67 Substrate + C3a → C3a 12 µM-1 min-1 
#68 (C9, APAF) → C9a log(2)/2.3 min-1 
#69 Smacmito → SMAC log(2)/7 min-1 
 Supplementary Table II: Parameter value selection 
Parameter ranges used for all screenings. (First column) Parameter ID as defined in Supplementary 
Table I; (Second column) Parameters selected for parameter set ‘I’; (Third column) Parameter rank 
according to their influence as determined by individual assessment (see methods and Fig. 2D); 
(Fourth column) Parameters selected for parameter set ‘C’; (Fifth column) Parameter rank according 
to their influence as determined by co-operative assessment (see supplementary methods and Fig. 3 in 
the paper); (Sixth column) Minimum value for screening range of this parameter; (Seventh column) 
Maximum value for screening range of this parameter; (Last column) Reference for experimentally 
determined parameter values. 
 Parameter set ‘I’ Parameter set ‘C’ Screening range 
id selected rank selected rank min max reference 
#2 yes 2 yes 10 0.5 2 (1) 
#3 yes 1 yes 5 0.08 4 (2-5) 
#5 yes 4 yes 2 as #3 8 * #3 (5) 
#7 yes 7 yes 3 0.25 2 (6-8) 
#8 yes 6  13 0.25 2 (6-8) 
#23 yes 5 yes 4 0.25 8 (2,3,9-12) 
#25  13 yes 8 0.25 2 (6,13,14) 
#32 yes 10  19 0.25 2 (15,16) 
#36 yes 9  41 0.25 2 (15,16) 
#54 yes 3 yes 9 0.17 1.2 (17) 
#67 yes 8 yes 6 0.25 8 (2,3,9,10,12,18) 
#68  21 yes 7 0.5 2 (19) 
#69  14 yes 1 0.75 1.5 (20) 
 
 
Supplementary Table III: Data summary for main text Fig. 5 
A detailed summary of all screenings (rows 2-7) as performed in the main text Fig. 5 A-F (Upper 
Panel). Absolute numbers of parameter value sets that passed criterion ‘PX’, criterion ‘PX’ and 
criterion ‘S80’ for a specific cell, criterion ‘PX’ and criterion ‘S80’ for combinations of cells for each 
screening; (middle Panel) same for percentage values; (lower panel) average and standard deviation 
over all screens. On average over all screenings, 19 +/- 6% standard deviation of the value 
combinations fulfilling criterion ‘PX’ (XIAP regulation for HeLa cells) and criterion ‘S80’ (time of 
80% substrate cleavage) for all cell lines. However, while on average 76 +/-16% sets fulfilled both 
criteria for HeLa and 81 +/- 19% for HCT-116 cells, only 24 +/- 2% of all value sets fulfilled criterion 
‘PX’ and criterion ‘S80’ for DLD-1 cells. 
  
  
 Parameter Set ‘C’ Parameter Set ‘I’ 
 
Brute 
Force 
100,000 
5 Par 
Monte 
Carlo 
1050 
5 Par 
Monte 
Carlo 
100,000 
5 Par 
Monte 
Carlo 
1,050,000 
10 Par 
Monte 
Carlo 
1,050,000 
10 Par 
Monte 
Carlo 
1,050 
5 Par 
criterion ‘PX’ 83948 986 92961 733068 579242 1003 
passed also criterion ‘S80’ for 
HeLa 80773 952 89145 634459 416452 1002 
HCT 83815 986 92893 729265 505481 1003 
DLD 24441 286 26426 242943 246944 213 
HeLa-DLD 21586 263 23786 152795 94766 212 
HeLa-HCT 80773 952 89145 634422 414942 1002 
DLD-HCT 24308 286 26358 239150 173223 213 
All cells 21586 263 23786 152758 93256 212 
  
Percentage Values 
criterion ‘PX’ 84 94 93 70 55 96 
passed also criterion ‘S80’ for 
HeLa 81 91 89 60 40 95 
HCT 84 94 93 69 48 96 
DLD 24 27 26 23 24 20 
HeLa-DLD 22 25 24 15 9 20 
HeLa-HCT 81 91 89 60 40 95 
DLD-HCT 24 27 26 23 16 20 
All cells 22 25 24 15 9 20 
 
Overall Average % SD % 
criterion ‘PX’ 82 16 
passed also criterion ‘S80’ for 
HeLa 76 22 
HCT 81 19 
DLD 24 2 
HeLa-DLD 19 6 
HeLa-HCT 76 22 
DLD-HCT 23 4 
All cells 19 6 
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